Information for the public
Elacestrant (Korserdu) is available on the NHS. It is a possible treatment for oestrogen receptor-positive HER2-negative locally advanced or metastatic breast cancer with an activating ESR1 mutation that has got worse after at least 12 months of endocrine therapy plus a cyclin-dependent kinase 4 and 6 inhibitor. It is available for:
- women, trans men and non-binary people who have been through the menopause
- trans women and men.
Cancer is described as locally advanced when it has spread to nearby tissues. Metastatic cancer has spread to other parts of the body.
If you are not eligible for elacestrant but are already having it, you should be able to continue until you and your healthcare professional decide when best to stop.
Is this treatment right for me?
Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See our webpage on making decisions about your care.
Questions to think about
- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?
Information and support
The NHS webpages on breast cancer in women and breast cancer in men may be a good place to find out more.
These organisations can give you advice and support:
- Breast Cancer Now, 0333 20 70 300
- METUPUK, join-us@metupuk.org.uk
- Make 2nds Count, 0131 357 4811
- Cancer Research UK, 0808 800 4040
- Macmillan Cancer Support, 0808 808 0000
You can also get support from your local Healthwatch.
NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.
ISBN: 978-1-4731-6828-2
This page was last updated: